Based on the efficacy of AR-R17779 treatment on reducing tumor progression in several models of TNBC, and evidence that CHRNA7 action in tumor-associated immune cells is relevant in adaptive immunity, we tested the effect of combination therapy of AR-R17779 with an anti-PD-L1 antibody (Fig. 6A). The gene discussed is CHRNA7; the disease is neoplasm.